To determine the interaction of M 3 muscarinic receptors (M 3 AChR) and P2X 7 receptors to increase intracellular [Ca 2ϩ ] ([Ca 2ϩ ] i ) and stimulate protein secretion in rat lacrimal gland cells. METHODS. Exorbital lacrimal glands from male Sprague-Dawley rats were divided into pieces or digested with collagenase to form acinar clumps. [Ca 2ϩ ] i was measured using an imaging system in acini incubated with fura-2/AM. Adenosine triphosphate (ATP) release was determined using the luciferin-luciferase reaction. Peroxidase secretion, our index for protein secretion, was measured spectrophotometrically. Acini were stimulated with the P2X 7 receptor agonist, (benzoylbenzoyl)adenosine 5Ј triphosphate (BzATP), cholinergic agonist carbachol, or the activator of conventional and novel PKC isoforms, phorbol 12-myristate 13-acetate (PMA Sci. 2011;52:3381-3390)
L acrimal glands secrete protein, electrolytes, and water into the tear film that overspreads the cornea and conjunctiva. 1 Lacrimal gland protein secretion is stimulated by multiple neurotransmitters, including the parasympathetic neurotransmitters acetylcholine (activates muscarinic type 3 acetylcholine receptors [M 3 AChR]) and vasoactive intestinal peptide (VIP) (stimulates VIPAC1 receptors) and the sympathetic neurotransmitter norepinephrine (interacts with ␣ 1D -adrenergic receptors [␣ 1D -AR]). 1 Each of these neurotransmitters activates a separate distinct signaling pathway. Thus lacrimal gland protein secretion can be induced by increasing the intracellular [Ca 2ϩ ] ([Ca 2ϩ ] i ) and activating protein kinase C (PKC), raising the cellular level of cAMP, or elevating cellular cGMP levels. [2] [3] [4] [5] [6] Cholinergic agonists stimulate lacrimal gland protein secretion by activating M 3 AChR coupled to G␣q G proteins, which activate phospholipase C␤ (PLC␤). 7, 8 PLC␤ activation cleaves phosphatidylinositol 1,4-bisphosphate to produce the PKC activator diacylglycerol and inositol 1,4,5-trisphosphate (InsP 3 ). InsP 3 activates Ca 2ϩ -selective InsP 3 receptors located in the endoplasmic reticulum of lacrimal gland acinar cells that increase the [Ca 2ϩ ] i . 2 Depletion of the endoplasmic reticulum Ca 2ϩ pool triggers extracellular Ca 2ϩ influx and a sustained elevation of [Ca 2ϩ ] i . 9 The increase in [Ca 2ϩ ] i along with activation of the PKC isoforms PKC␣, PKC␦, and PKC stimulate the secretion of protein stored in preformed secretory granules. 3 Protein secretion occurs across the apical membrane and along with isotonic electrolyte and water secretion, also induced by cholinergic agonists, forms lacrimal gland fluid. 10 After modification by ductal cell secretion, lacrimal gland fluid is secreted onto the cornea and conjunctiva.
In addition to M 3 AChR, VIPAC1, and ␣ 1D -AR, lacrimal gland acinar cells express purinergic P2 receptors that are coupled to an increase in [Ca 2ϩ ] i and stimulate protein secretion. 11 The P2 receptor family consists of P2Y receptors that are G-protein-coupled (metabotropic) and P2X receptors that are ion channels (ionotropic). 12 Both types of P2 receptors are activated by extracellular di-and tri-nucleotides. P2Y receptors cause an increase in [Ca 2ϩ ] i by InsP 3 -induced Ca 2ϩ mobilization from intracellular stores similar to muscarinic receptors, whereas P2X receptors act as ligand-gated, nonselective ion channels that allow the influx of extracellular Ca 2ϩ . 12 P2X 7 receptors are a major functional P2 receptor in the lacrimal gland. 11 Activation of P2X 7 receptors with (benzoylbenzoyl)adenosine 5Ј triphosphate (BzATP) causes an increase in [Ca 2ϩ ] i and the stimulation of lacrimal gland protein secretion. 11 The BzATP-stimulated increase in [Ca 2ϩ ] i in lacrimal acinar cells was increased in the absence of Mg 2ϩ and was blocked by two P2X 7 antagonists, brilliant blue G and A438979. 11 Similarly, protein secretion induced by BzATP was prevented by brilliant blue G. 11 Thus the activation of P2X 7 receptors is a Ca 2ϩ -dependent stimulus of lacrimal gland protein secretion.
Neurotransmitters often work together, thus changing the secretory response. Simultaneous activation of two different receptors and their signaling pathways can cause three different outcomes: a less than additive response, an additive response, or potentiation of the response. A less than additive response can occur if two receptors activate the same or overlapping signaling pathways or if activation of one receptor inhibits the second receptor. In the lacrimal gland, a less than additive secretory response occurs when the cholinergic agonist M 3 AChR is activated with carbachol and PKC isoforms are activated by the phorbol ester 4␤-phorbol 12,13 dibutyrate (PdBU) because M 3 AChR and PdBU both activate PKC isoforms. 13 An additive response results if two receptors use different signaling pathways. No interaction of two separate signaling pathways occurs in the lacrimal gland in the presence of activation of the M 3 AChR (Ca 2ϩ -and PKC-dependent) and the ␣ 1D -AR (cGMP-and Ca 2ϩ -dependent), leading to additivity of secretion. 13 Finally, potentiation is produced if the two pathways interact synergistically and cause a response that is greater than that of the two pathways activated together. In the lacrimal gland interaction of M 3 AChR (Ca 2ϩ -and PKC-dependent) and VIPAC1 (cAMP and Ca 2ϩ -dependent) receptors stimulated by cholinergic agonists and VIP, respectively, leads to potentiation. 13, 14 In the present study the interaction of M 3 
MATERIALS AND METHODS

Materials
Fura-2 tetra-acetoxylmethyl ester (fura-2/AM) and reagent (Amplex Red) were purchased from Invitrogen Corporation (Carlsbad, CA). Collagenase CLSIII was from Worthington Biochemicals (Lakewood, NJ), and phorbol 12-myristate 13-acetate (PMA) was from LC Laboratories (Woburn, MA). All other chemicals were from Sigma-Aldrich (St. Louis, MO).
Animals
All experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Schepens Eye Research Institute Animal Care and Use Committee. Male Sprague-Dawley rats weighing 125 to 150 g were purchased from Taconic Farms (Germantown, NY). Rats were maintained in rooms at constant temperature with fixed light-dark intervals of 12 hours and were fed ad libitum. They were anesthetized for 1 minute in CO 2 and then decapitated. Both exorbital lacrimal glands were removed immediately.
Preparation of Lacrimal Gland Acini
Collagenase digestion was used to prepare acini. Lacrimal glands were fragmented before incubation at 37°C with collagenase CLSIII (100 U/mL) in Krebs-Ringer bicarbonate buffer with HEPES (KRB-HEPES) (119 mM NaCl, 4.8 mM KCl, 1.0 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 25 MM NaHCO 3 , 10 mM HEPES, and 5.5 mM glucose, at pH 7.45) plus 0.5% BSA. After incubation, fragments were triturated, filtered through nylon mesh (150-M pore size), and centrifuged at 50g for 2 minutes. The pellet was washed twice through KRB-HEPES containing 4% BSA. The dispersed acini recovered for 60 minutes at 37°C before use.
Measurement of [Ca 2؉ ] i
Acini were incubated for 30 minutes at room temperature in the dark with KRB-HEPES containing 0.5% BSA, 0. 
Measurement of ATP Release
Lacrimal glands were removed and minced into small pieces, or acini were prepared by collagenase digestion. Pieces or acini were placed in cell strainers and preincubated in 0.4% BSA in KRB for 1 hour in a 12-well culture dish at 37°C. The strainers were moved to new wells containing fresh 0.4% BSA in KRB for an additional hour. The pieces or acini were then placed in fresh 0.4% BSA in KRB containing 10 Ϫ4 M ARL-67516, ␣,␤ methylene ADP, and ␤,␥ methylene ATP, inhibitors of ectonucleotide pyrophosphatase and ectoATPase. Agonists were added for 10 minutes, and the lacrimal gland pieces were removed. The ATP concentrations in the supernatants were determined with the chemiluminescent luciferin-luciferase reaction using an ATP assay kit (FLAA; Sigma-Aldrich, St. Louis, MO). The luciferin-luciferase working solution was 100 L stock solution to 1 mL assay buffer, according to the manufacturer's instructions. Twenty-five microliters of samples were added to a 96-well plate and were placed in a luminometer (Synerg Mx microplate reader; BioTek Instruments, Winooski, VT). The luciferin-luciferase working solution (15 L) was injected into each well using the internal injector system. The emitted light was recorded with an integration time of 100 ms/measurement every minute for 10 minutes. ATP levels were calculated by integration under the luminescence curve. Luminescence was converted to ATP concentration using an ATP standard curve. Data were expressed as fold increase above basal.
Expression of Constitutively Active and Dominant-Negative PKC Isoforms
Replication-defective adenovirus constructs expressing green fluorescent protein and dominant-negative PKC␣ or PKC were kind gifts from George King (Joslin Diabetes Center, Boston, MA). Constitutively active PKC␣ (myrPKC␣) was used as described previously. 15 Acini were incubated overnight in the presence of 1 ϫ 10 7 pfu of each adenovirus. Acini were allowed to recover for 1 hour before the addition of fura-2/AM for 1 hour.
Measurement of Peroxidase Secretion
Acini were incubated for 40 minutes in KRB-HEPES containing 4% BSA at 37°C in the presence of agonists. Inhibitors or antagonists were added 20 minutes before agonists. To terminate the incubation, acini were pelleted by centrifugation, and the supernatant was collected. The pellet was homogenized in 10 mM Tris-HCl (pH 7.5). Peroxidase activity, an index of protein secretion, was measured in duplicate in both the supernatant and the pellet. Peroxidase was measured using a reagent (Amplex Red; Invitrogen), which, when oxidized by peroxidase in the presence of hydrogen peroxide, produces a highly fluorescent molecule. The amount of fluorescence in the supernatant and pellet was quantified using a fluorescence microplate reader (model FL600; BioTek) with an excitation wavelength of 530 nm and an emission wavelength of 590 nm. Peroxidase was expressed as a percentage of peroxidase secreted into the media (supernatant) compared with total peroxidase present in the cells before stimulation (pellet plus supernatant). Data were expressed as fold increase ϫ basal, which was set to 1.
Statistical Analysis
Results were expressed as mean Ϯ SEM. Data were analyzed by Student's t-test. P Ͻ 0.05 was considered statistically significant. was not dependent on BzATP activation and that the muscarinic receptor activation preceded that of P2X 7 receptors. These data also suggest that the activation of P2X 7 receptors did not inhibit activation of the M3AChR-induced Ca 2ϩ signaling pathway.
RESULTS
Activation of PKC Isoforms Does Not Alter the P2X 7 Receptor-Stimulated Increase in [Ca
2؉ ] i in Lacrimal Gland Acini
Given that the stimulation of M 3 AChR induces P2X 7 receptor activity, we investigated the mechanism by which this occurs. Two possible mechanisms were the intracellular mediators produced by M3AChR stimulation activating the P2X 7 receptor and the M 3 AChR-induced release of ATP into the extracellular space. We investigated one intracellular pathway stimulated by the activation of M 3 AChR-that is, the induction of PKC isoform activity. We first determined whether the activation of PKC isoforms alters the P2X 7 site, effects on function. 3 Because PMA activates conventional and novel PKC isoforms, we sought to determine whether activation of the PKC␣ or inhibition of the PKC␣ or PKC alters the P2X 7 receptor effect on [Ca 2ϩ ] i using adenoviruses that induced the expression of constitutively active PKC␣ (myrPKC␣) or dominant-negative PKC␣ or PKC. We previously showed that myrPKC␣ increased basal protein secretion from lacrimal gland acini, 15 whereas dominant-negative PKC␣ and PKC inhibited EGF-stimulated conjunctival goblet cell proliferation. 18 
Cholinergic Agonists Release ATP from Lacrimal Gland Pieces but Not from Acini
We sought to determine whether cholinergic agonists release ATP that could activate P2X 7 receptors. Pieces of lacrimal gland were stimulated with no agonists (basal) or the cholinergic agonist carbachol (10 Ϫ4 M). Basal ATP release was set to 1, and carbachol significantly increased the release 1.5 Ϯ 0.1-fold (Fig. 8A) . Preincubation with atropine at 10 Ϫ4 M completely blocked carbachol-stimulated ATP release. To determine whether cholinergic agonists release ATP from acini, acini were stimulated with no agonists (basal) or carbachol at 10 Ϫ4 M. Carbachol did not alter ATP release compared with basal, which was set to 1 (Fig. 8B) . To confirm that cholinergic agonists did not stimulate ATP release from acini, acini were preincubated with apyrase, which breaks down extracellular ATP into AMP that can be converted to adenosine and should thus prevent cholinergic agonist activation of P2X 7 receptors. Apyrase did not alter the carbachol-stimulated increase in [Ca 2ϩ ] i from acinar cells (Figs. 5A, 5B) . We conclude that cholinergic agonists release ATP from lacrimal gland pieces that contain nerve endings, acinar cells, myoepithelial cells, and duct cells but not from acini that are composed of acinar and myoepithelial cells. Thus M 3 AChR do not release ATP from acini to activate P2X 7 receptors but do release it when other cell types are present. M 3 AChR could release ATP to activate P2X 7 in vivo and thus have a physiological function. The M 3 AChR release of ATP, however, did not activate P2X 7 receptors in the current experiments that used acini. Hence, another mechanism is responsible.
Cholinergic Agonists Activate P2X 7 Receptors to Stimulate Protein Secretion from Lacrimal Gland Acinar Cells
Given that cholinergic agonists activate P2X 7 receptors to increase the [Ca 2ϩ ] i , we sought to determine whether this effect was extended to the entire signaling pathway, resulting in protein secretion. Lacrimal gland acini were stimulated with the cholinergic agonist carbachol at 10 Ϫ4 M, which increased secretion by 1.3 Ϯ 0.1-fold (Fig. 9A) . Preincubation with the P2X 7 inhibitor A438079 (10 Ϫ4 M) did not alter carbachol-stimulated secretion. Lacrimal gland acini were stimulated with BzATP at 10 Ϫ4 M, and protein secretion was measured. BzATP significantly stimulated protein secretion by 1.5 Ϯ 0.1-fold (Fig. 9B) . When cells were preincubated with the cholinergic antagonist atropine (10 Ϫ4 M), BzATP-stimulated secretion was almost completely blocked. As for the increase in [Ca 2ϩ ] i , the activation of P2X 7 receptors did not alter cholinergic agonist-induced secretion. In contrast, the activation of M 3 AChR induced P2X 7 receptors to stimulate lacrimal gland protein secretion.
Cholinergic and P2X 7 Receptor Agonists Activate Different Cellular Pathways to Stimulate Protein Secretion from Lacrimal Gland Acini
Protein secretion was measured from acini stimulated simultaneously with carbachol and BzATP at maximal concentrations for secretion. Carbachol (10 Ϫ4 M) and BzATP (10 Ϫ4 M) each increased protein secretion (Fig. 10A) . When the two agonists were added simultaneously, the increase in protein secretion was not significantly different from the calculated additivity. Similar results were obtained when this experiment was performed in the absence of Mg 2ϩ to increase the P2X 7 receptor response (Fig. 10B) 
DISCUSSION
In the present study, we demonstrated that one mechanism by which cholinergic agonists stimulate lacrimal gland protein secretion is to activate P2X 7 receptors. In this tissue, cholinergic agonists activate P2X 7 receptors to increase the [Ca 2ϩ ] i and stimulate secretion. There are multiple mechanisms by which activated muscarinic agonists can stimulate P2X 7 receptors. The mechanisms include the release of ATP, the production of intracellular signaling compounds, and the direct interaction of receptors. We found that cholinergic agonists did not release ATP from acini in which cholinergic antagonists decrease the activity of the P2X 7 receptors. In exocrine glands, ATP, which stimulates P2X 7 receptors, can come from multiple sources, including nerves, myoepithelial cells, acinar cells, and ductal cells. In the present study, the activation of muscarinic receptors caused the release of ATP from lacrimal gland pieces, but not from acini, implying that either nerves or duct cells are the source of ATP. The data indicating the lack of ATP release from acini are robust. Two different methods were used to investigate ATP release, and a positive control (phenylephrine, data not shown) induced ATP release. Our finding was in agreement with the results of Novak et al., 19 who found similar results from their preparation that included isolated acini and small ducts. However, the release of ATP did not account for cholinergic activation of P2X 7 receptors when acini alone were used, as in the present study.
The second mechanism by which cholinergic agonists can activate or alter the activity of the P2X 7 receptor is the production of second messengers that would directly interact with the intracellular domains of the P2X 7 receptor or the P2X 7 -induced production of signaling intermediates. G-protein-coupled receptors often alter P2X 7 activity by the activation of PKC or the release of Ca 2ϩ from intracellular stores. All P2X receptor types have a consensus site for PKC phosphorylation on the intracellular C terminus. 20 Brown and Yule 21 found, however, that PKC catalytic subunits did not phosphorylate P2X 3 , P2X 4 , or P2X 7 receptors in transfected cells. However, Faria et al. 22 found that the inhibition of PKC as well as MAPK, PI3K, and cytoskeletal proteins blocked ATP induction of large conductance pores. Using multiple experimental paradigms, we found that the activation of PKC isoforms by phorbol esters, constitutively active PKC␣, dominant-negative PKC␣, or dominant-negative PKC did not alter the P2X 7 receptor-stimulated increase in [Ca 2ϩ ] i in lacrimal gland acini. Thus it appears that modulation of the P2X 7 receptors by PKC isoforms activated by cholinergic agonists does not lead to activation of the P2X 7 receptors to increase [Ca 2ϩ ] I in lacrimal gland acini. Alteration of the P2X 7 receptor by other signaling compounds or by direct interaction with the M 3 AChRs (a third mechanism for activation) has yet to be tested.
We found that cholinergic-and P2X 7 Values are mean Ϯ SEM from four independent experiments. *Significant difference from no addition. n.s., no significant difference.
